Healthcare provider profile · identity verified

John P Thomas, MD

Family Practice · EL PASO, TX · NPI 1144229766

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1153	382
Lisinopril	Lisinopril	550	194
Metformin Hcl	Metformin Hcl	498	177
Amlodipine Besylate	Amlodipine Besylate	425	165
Levothyroxine Sodium	Levothyroxine Sodium	346	114
Simvastatin	Simvastatin	282	91
Losartan Potassium	Losartan Potassium	267	103
Rosuvastatin Calcium	Rosuvastatin Calcium	211	75
Omeprazole	Omeprazole	202	80
Tamsulosin Hcl	Tamsulosin Hcl	199	70
Gabapentin	Gabapentin	180	72
Metoprolol Succinate	Metoprolol Succinate	141	46
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	125	44
Hydrochlorothiazide	Hydrochlorothiazide	123	49
Montelukast Sodium	Montelukast Sodium	116	37
Glipizide	Glipizide	108	37
Januvia	Sitagliptin Phosphate	102	42
Allopurinol	Allopurinol	101	28
Metoprolol Tartrate	Metoprolol Tartrate	97	33
Carvedilol	Carvedilol	79	37
Pantoprazole Sodium	Pantoprazole Sodium	78	33
Pravastatin Sodium	Pravastatin Sodium	78	28
Jardiance	Empagliflozin	77	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	75	26
Tramadol Hcl	Tramadol Hcl	70	32
Pioglitazone Hcl	Pioglitazone Hcl	69	24
Alendronate Sodium	Alendronate Sodium	68	31
Furosemide	Furosemide	63	28
Sertraline Hcl	Sertraline Hcl	63	23
Trazodone Hcl	Trazodone Hcl	63	29
Albuterol Sulfate Hfa	Albuterol Sulfate	62	29
Alprazolam	Alprazolam	61	22
Finasteride	Finasteride	58	19
Bydureon Bcise	Exenatide Microspheres	57	21
Acetaminophen-Codeine	Acetaminophen With Codeine	55	24
Ibuprofen	Ibuprofen	54	27
Glimepiride	Glimepiride	53	20
Fluticasone Propionate	Fluticasone Propionate	52	24
Clopidogrel	Clopidogrel Bisulfate	50	20
Chlorthalidone	Chlorthalidone	44	17
Famotidine	Famotidine	42	19
Telmisartan	Telmisartan	42	15
Meloxicam	Meloxicam	41	18
Clonazepam	Clonazepam	39	12
Eliquis	Apixaban	39	15
Hydralazine Hcl	Hydralazine Hcl	33	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	13
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Buspirone Hcl	Buspirone Hcl	31	14
Escitalopram Oxalate	Escitalopram Oxalate	31	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Potassium Chloride	Potassium Chloride	31	14
Tizanidine Hcl	Tizanidine Hcl	31	12
Metformin Hcl Er	Metformin Hcl	30	14
Spironolactone	Spironolactone	30	14
Olmesartan Medoxomil	Olmesartan Medoxomil	29	12
Trulicity	Dulaglutide	29	14
Naproxen	Naproxen	28	14
Venlafaxine Hcl	Venlafaxine Hcl	28	suppressed
Benazepril Hcl	Benazepril Hcl	27	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	27	14
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Donepezil Hcl	Donepezil Hcl	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	14
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Lorazepam	Lorazepam	23	suppressed
Mounjaro	Tirzepatide	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Glipizide Er	Glipizide	22	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Ozempic	Semaglutide	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Synthroid	Levothyroxine Sodium	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	12
Candesartan Cilexetil	Candesartan Cilexetil	19	suppressed
Meclizine Hcl	Meclizine Hcl	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Celecoxib	Celecoxib	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Atrovent Hfa	Ipratropium Bromide	16	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	16	suppressed
Baclofen	Baclofen	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan	Valsartan	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Temazepam	Temazepam	12	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error